Patent intelligence · US
US 11278493
Ophthalmic formulations providing durable ocular lubrication
Ophthalmic formulations providing durable ocular lubrication
Patent details — US 11278493
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 22, 2022
- Expiration
- Mar 17, 2042
- Applicant
- ETERNATEAR, INC.
- Claims
- 7
- CPC classes
- A61K, A61K35/644, A61K47/14, A61K47/44
Quick answer
US 11278493 (Ophthalmic formulations providing durable ocular lubrication) is held by ETERNATEAR, INC.. Status: granted. Granted Mar 22, 2022. Expires Mar 17, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ETERNATEAR, INC.
- Grant date
- Expiration
- Claims
- 7
- CPC classes
- A61K, A61K35/644, A61K47/14, A61K47/44, A61K9/0048, A61K9/107
More from ETERNATEAR, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12226429
Highly active compounds against COVID-19
granted -
US 12084473
β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
granted -
US 12006340
Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
granted -
US 12005139
Ophthalmic formulations and related methods
granted -
US 11975016
2′-substituted-N6-substituted purine nucleotides for RNA virus treatment
granted -
US 11964047
Ophthalmic formulations and related methods
granted -
US 11833160
Ursodeoxycholic acid derivatives as HDAC inhibitors for the treatment of polycystic diseases
granted -
US 11813278
Highly active compounds against COVID-19
granted
Frequently asked questions
What is US patent 11278493?
US 11278493 (Ophthalmic formulations providing durable ocular lubrication) is held by ETERNATEAR, INC.. Status: granted. Granted Mar 22, 2022. Expires Mar 17, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11278493?
ETERNATEAR, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 35 pharmaceutical patents for this assignee.
When does US 11278493 expire?
Our index shows an expiration date of Mar 17, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.